Cargando…

Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight

The coronavirus disease 2019 (COVID-19) outbreak has drawn the scientific community's attention to pre-existing metabolic conditions that could aggravate the infection, causing extended viral shedding, prolonged hospitalization, and high death rates. Metabolic dysfunction-associated fatty liver...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vasques-Monteiro, Isabela Macedo Lopes, Souza-Mello, Vanessa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072197/ https://www.ncbi.nlm.nih.gov/pubmed/33967554 http://dx.doi.org/10.3748/wjg.v27.i16.1738

Ejemplares similares

Coronavirus disease 2019 in liver transplant patients: Clinical and therapeutic aspects
por: Loinaz-Segurola, Carmelo, et al.
Publicado: (2021)

Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice
por: Silva-Veiga, Flavia Maria, et al.
Publicado: (2022)

Obese children with fatty liver: Between reality and disease mongering
por: Ranucci, Giusy, et al.
Publicado: (2017)

Implications of metabolic dysfunction associated fatty liver disease in COVID-19
por: Chakraborty, Raja, et al.
Publicado: (2023)

Clinical features and potential mechanism of coronavirus disease 2019-associated liver injury
por: Han, Mei-Wen, et al.
Publicado: (2021)

De novo and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation
por: Han, Ma Ai Thanda, et al.
Publicado: (2021)

Coronavirus disease 2019 and renal transplantation
por: Nassar, Mahmoud, et al.
Publicado: (2021)

Fatty liver without a large “belly”: Magnified review of non-alcoholic fatty liver disease in non-obese patients
por: Yousef, Mohamad H, et al.
Publicado: (2017)

Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: Is this plausible?
por: Devi, Jalpa, et al.
Publicado: (2022)

Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in coronavirus disease 2019 patients
por: Leowattana, Wattana
Publicado: (2021)

Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis
por: Pal, Shreya C, et al.
Publicado: (2023)

Non-alcoholic fatty liver disease
por: Neuschwander-Tetri, Brent A.
Publicado: (2017)

Viral Proteases as Targets for Coronavirus Disease 2019 Drug Development
por: Zhu, Wei, et al.
Publicado: (2021)

Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
por: Fassio, Eduardo, et al.
Publicado: (2022)

Mediterranean diet and nonalcoholic fatty liver disease
por: Anania, Caterina, et al.
Publicado: (2018)

Fatty liver and celiac disease: Why worry?
por: Narciso-Schiavon, Janaina Luz, et al.
Publicado: (2023)

Rhino-orbital-cerebral mucormycosis as a complication of coronavirus disease 2019
por: Al-Ani, Raid M
Publicado: (2022)

Hepatic manifestations of coronavirus disease 2019 infection: Clinical and laboratory perspective
por: Hanif, Farina M, et al.
Publicado: (2022)

Non-alcoholic fatty liver disease and cardiovascular risk
por: Patil, Rashmee, et al.
Publicado: (2017)

COVID-19 and pediatric fatty liver disease: Is there interplay?
por: Di Sessa, Anna, et al.
Publicado: (2021)

Liver and COVID-19: From care of patients with liver diseases to liver injury
por: Gaspar, Rui, et al.
Publicado: (2021)

Growing challenge of post-liver transplantation non-alcoholic fatty liver disease
por: Kalogirou, Maria Styliani, et al.
Publicado: (2022)

Relationship between non-alcoholic fatty liver disease and coronary heart disease
por: Arslan, Ugur, et al.
Publicado: (2020)

Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
por: Wong, Carrie R, et al.
Publicado: (2016)

Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma
por: Said, Adnan, et al.
Publicado: (2017)

Associations between nonalcoholic fatty liver disease and ischemic stroke
por: Alkagiet, Stelina, et al.
Publicado: (2018)

Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity
por: Pirola, Carlos J, et al.
Publicado: (2018)

Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics
por: Di Sessa, Anna, et al.
Publicado: (2021)

Management of metabolic-associated fatty liver disease: The diabetology perspective
por: Jeeyavudeen, Mohammad Sadiq, et al.
Publicado: (2023)

Emerging role of engineered exosomes in nonalcoholic fatty liver disease
por: Ding, Jian, et al.
Publicado: (2023)

Impact of coronavirus disease 2019 on prevention and elimination strategies for hepatitis B and hepatitis C
por: Rehman, Syed Tabish, et al.
Publicado: (2021)

Presentation and outcome of myocardial infarction with non-obstructive coronary arteries in coronavirus disease 2019
por: John, Kevin, et al.
Publicado: (2022)

Management of neurosurgical patients during coronavirus disease 2019 pandemics: The Ljubljana, Slovenia experience
por: Velnar, Tomaz, et al.
Publicado: (2022)

The globe on the spotlight: Coronavirus disease 2019 (Covid-19)
por: Brida, Margarita, et al.
Publicado: (2020)

Metabolic associated fatty liver disease: Addressing a new era in liver transplantation
por: Gill, Madeleine G, et al.
Publicado: (2020)

Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?
por: Dietrich, Christoph G, et al.
Publicado: (2023)

Racial differences in prevalence and severity of non-alcoholic fatty liver disease
por: Bonacini, Maurizio, et al.
Publicado: (2021)

Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge
por: Mattos, Ângelo Z, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease and COVID-19: An epidemic that begets pandemic
por: Ahmed, Musaab, et al.
Publicado: (2021)

Therapies for non-alcoholic fatty liver disease: A 2022 update
por: Shen, Katie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f4pknrlmtmehqot2if0qa8v6pj